#Lymsm

Some #ASH20 DLBCL thoughts and observations. I feel like we are at the tip of a changing landscape for therapy and trial design in DLBCL, both newly dx and R/R.
Read more
Tons of great teaching pearls from this phenomenal PET/CT in #lymphoma session. Will start a #thread here. #ASH20 #lymsm First, staging PET for DLBCL is more sensitive than BMBx for
Read more
Looking forward to moderating oral presentations on biomarkers and prognostication in aggressive #lymphoma with @SoniSmithMD on Monday morning. We have some exciting #ASH20 abstracts to discuss. https://ash.confex.com/ash/2020/webprogram/Se
Read more
#lymphomafacts - Burkitt-1Dennis Burkitt - #medicalhero- missionary surgeon Uganda- 1953: described children with jaw tumours- worked out link with malaria- cell culture to Epstein who saw inclusions, EBV discovered- other
Read more
Is Autologous HCT in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era? Question examined by @CIBMTR @niravshahmd @timfenske#bmtsm #lymsm (1/6)https://pubmed.ncbi.nlm.nih.gov/33120429/  249 PET+ DLBCL p
Read more
Two provoking abstracts on CNS prophylaxis at #ASH2020. Credit to the U.S & Canadian authors for attempting to address the thorny issue of CNSp in DLBCL.However: substantial biases & lack
Read more
Excited to share updated data of the GHSG phase II NIVAHL trial investigating sequential and concomitant Nivo + AVD 1st-line treatment in early-stage unfavorable #Hodgkin lymphoma at @ASH_hematology: https://bit.ly/2LgW0g5 
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.